Ablating VHL in rod photoreceptors modulates RPE glycolysis and improves preclinical model of retinitis pigmentosa
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci185796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Salvatore Marco Caruso und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Glycolysis, Von Hippel-Lindau Tumor Suppressor Protein, Retinal Rod Photoreceptor Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Eye Institute, Foundation Fighting Blindness.
Abstract (Originalsprache)
Neuroretinal degenerations including retinitis pigmentosa (RP) comprise a heterogeneous collection of pathogenic mutations that ultimately result in blindness. Despite recent advances in precision medicine, therapies for rarer mutations are hindered by burdensome developmental costs. To this end, Von Hippel-Lindau (VHL) is an attractive therapeutic target to treat RP. By ablating VHL in rod photoreceptors and elevating hypoxia-inducible factor (HIF) levels, we demonstrate a path to therapeutically enhancing glycolysis independent of the underlying genetic variant that slows degeneration of both rod and cone photoreceptors in a preclinical model of retinitis pigmentosa. This rod-specific intervention also resulted in reciprocal, decreased glycolytic activity within the retinal pigment epithelium (RPE) cells despite no direct genetic modifications to the RPE. Suppressing glycolysis in the RPE provided notable, noncell-autonomous therapeutic benefits to the photoreceptors, indicative of metabolically sensitive crosstalk between different cellular compartments of the retina. Surprisingly, targeting HIF2A in RPE cells did not impact RPE glycolysis, potentially implicating HIF1A as a major regulator in mouse RPE and providing a rationale for future therapeutic efforts aimed at modulating RPE metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Columbia University, New York, New York, USA.
- Jonas Children's Vision Care and Bernard & Shirlee Brown Glaucoma Laboratory, Institute of Human Nutrition, Columbia Stem Cell Initiative, New York, New York, USA.
- Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
- Department of Biochemistry, The University of Washington, Seattle, Washington, USA.
- Department of Ophthalmology and Visual Sciences and.
- Department of Biochemistry and Molecular Medicine, West Virginia University, Morgantown, West Virginia, USA.
Förderung
- NEI NIH HHS
- National Eye Institute
- Foundation Fighting Blindness
Zitieren
APA
Caruso, S. M., Cui, X., Robbings, B. M., Heapes, N., Demirkol, A., Lopes Da Costa, B., Hass, D. T., Quinn, P. M., Du, J., Hurley, J. B., & Tsang, S. H. (2025). Ablating VHL in rod photoreceptors modulates RPE glycolysis and improves preclinical model of retinitis pigmentosa. Journal of Clinical Investigation. https://doi.org/10.1172/jci185796
Vancouver
Caruso SM, Cui X, Robbings BM, Heapes N, Demirkol A, Lopes Da Costa B, et al. Ablating VHL in rod photoreceptors modulates RPE glycolysis and improves preclinical model of retinitis pigmentosa. Journal of Clinical Investigation. 2025. doi:10.1172/jci185796
BibTeX
@article{Caruso2025,
author = {Caruso, Salvatore Marco and Cui, Xuan and Robbings, Brian M and Heapes, Noah and Demirkol, Aykut and Lopes Da Costa, Bruna and Hass, Daniel T and Quinn, Peter Mj and Du, Jianhai and Hurley, James B and Tsang, Stephen H},
title = {Ablating VHL in rod photoreceptors modulates RPE glycolysis and improves preclinical model of retinitis pigmentosa},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci185796}
}
EUVIMED